3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Fasting
9
Prostatic Neoplasms
3
Breast Neoplasms
3
Intermittent Fasting
2
Colorectal Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma
1
Liposarcoma
1
Infertility
1
Histiocytoma, Malignant Fibrous
1
Glioma
1
Fibrosis
1
Fasting in Malignant Solid Tumors
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Childhood Cancer Survivors
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
444
Rituximab
401
Etoposide
224
Vincristine
215
Doxorubicin
201
Filgrastim
200
Prednisone
176
Cytarabine
159
Radiotherapy
152
fludarabine phosphate
147
Methotrexate
137
Peripheral Blood Stem Cell Transplantation
129
Melphalan
127
fludarabine
115
Busulfan
99
Dexamethasone
93
Tacrolimus
75
Carmustine
74
Granulocyte Colony-Stimulating Factor
73
Mycophenolic Acid
71
Gemcitabine
66
Bortezomib
65
Antilymphocyte Serum
65
Whole-Body Irradiation
62
Cyclosporine
62
Bendamustine Hydrochloride
62
Lenalidomide
60
Ifosfamide
58
sargramostim
51
Methylprednisolone
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoma
×
Angptl4 protein, mouse
×
Clear all
NCT06645093
2026-03-10
FasteStudien
University of Oslo
Phase NA
Enrolling by invitation
40 enrolled